Trial Search Results

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Sarepta Therapeutics, Inc.

Stanford Investigator(s):


  • Drug: Casimersen
  • Drug: Golodirsen


Phase 3


Inclusion Criteria:

   - Completed a clinical trial evaluating casimersen or golodirsen, per protocol.

   - Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.

Ages Eligible for Study

7 Years - 23 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305